glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

ADA 2026 Retatrutide Results: TRIUMPH-1 and TRANSCEND-T2D-1

ADA 2026 Retatrutide Results: TRANSCEND-T2D-1 and TRIUMPH-1

Event: ADA 86th Scientific Sessions · June 6-10, 2026 · New Orleans, LA · Ernest N. Morial Convention Center
Retatrutide results were presented at the ADA 86th Scientific Sessions on June 6, 2026. The session covered TRIUMPH-1 in obesity and TRANSCEND-T2D-1 in type 2 diabetes, including knee osteoarthritis and sleep-apnea findings from TRIUMPH-1's nested trials. TRANSCEND-T2D-1 was also published in The Lancet that day.
The distinction matters: conference data and a peer-reviewed paper are available, but retatrutide remains investigational. This page summarizes the meeting; the results guide tracks later readouts.

The Symposium

Title: Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results)
Date: Saturday, June 6, 2026 Time: 1:30 – 3:00 p.m. (Central Time) Location: Great Hall A, Ernest N. Morial Convention Center, New Orleans On-demand access: ADA advertised recordings for registered participants from June 10 – August 10, 2026. That access window has ended.

Confirmed Speakers and Topics

PresenterTopic
Jonathan Campbell, PhDTriple-agonist mechanism
Harpreet S. Bajaj, MDTRANSCEND-T2D-1 results in type 2 diabetes
Ania M. Jastreboff, MD, PhDTRIUMPH-1 results in obesity and its complications
See ADA's session report and Lilly's congress materials.

What Was Presented

TRIUMPH-1: Lilly reported mean weight loss of 28.3% at 12 mg over 80 weeks, using the efficacy estimand. This was not the first topline disclosure: Lilly had announced it on May 21, 2026. The ADA presentation added findings from the nested knee osteoarthritis and obstructive sleep-apnea trials.
TRANSCEND-T2D-1: The published trial randomized 537 adults with type 2 diabetes inadequately controlled with diet and exercise alone. At 40 weeks, weight loss with 12 mg was 16.8% on the efficacy estimand and 15.3% on the treatment-regimen estimand. These analyses answer different questions about treatment adherence; they should not be mixed. See the full diabetes trial summary.
Obesity complications: The TRIUMPH-1 nested trials reported improvements in knee pain and sleep-apnea severity. Read the knee osteoarthritis evidence and sleep-apnea results for the populations, endpoints, and limitations.

The results support further evaluation of retatrutide. They do not establish that it is superior to tirzepatide or semaglutide in a head-to-head trial.

Why ADA 2026 Matters

The meeting moved the discussion from topline announcements to detailed clinical results. The diabetes paper provides a peer-reviewed account of efficacy and adverse events, while the obesity presentation reports outcomes across weight, knee pain, and sleep apnea.

Conference presentation does not guarantee regulatory approval or insurance coverage. In its July 23 update, Lilly said it planned a U.S. Biologics License Application in Q1 2027. That is a submission plan, not an FDA decision date.

How to Follow the Data

Frequently Asked Questions

When is the retatrutide ADA 2026 session?

Saturday, June 6, 2026, 1:30-3:00 p.m. Central Time, at Great Hall A of the Ernest N. Morial Convention Center in New Orleans, as part of the ADA 86th Scientific Sessions (June 6-10, 2026).

What retatrutide data was presented at ADA 2026?

TRIUMPH-1 obesity results, its nested knee osteoarthritis and sleep-apnea findings, and TRANSCEND-T2D-1 diabetes results. The diabetes trial was simultaneously published in The Lancet.

Were TRIUMPH-1 results first announced at ADA 2026?

No. Lilly announced topline results on May 21, 2026, before the June 6 ADA presentation. ADA provided additional detail, including the obesity-complication results.

How can I access the recorded presentations?

ADA advertised on-demand recordings for registered attendees from June 10 through August 10, 2026. That window has ended; the linked ADA session report, congress materials, and journal paper remain the sources for this summary.

Sources

Medical disclaimer: This page summarizes reported scientific-session results. Retatrutide is not FDA approved. This is informational only, not medical advice. glp3.wiki is not affiliated with Eli Lilly, the ADA, or any pharmaceutical company.
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Related reading

TRANSCEND-T2D-1: Published Retatrutide Phase 3 Diabetes Results
News

TRANSCEND-T2D-1: Published Retatrutide Phase 3 Diabetes Results

Published Phase 3 diabetes results: 537 participants, 40 weeks, and distinct treatment-regimen and efficacy estimates.

TRIUMPH-3 Retatrutide Results: 22.6% at 12 mg
News

TRIUMPH-3 Retatrutide Results: 22.6% at 12 mg

July 2026 topline results in adults with severe obesity and established cardiovascular disease, with weight, safety and event-data limitations.

Retatrutide for Knee Osteoarthritis: TRIUMPH-4
Explainer

Retatrutide for Knee Osteoarthritis: TRIUMPH-4

Phase 3 weight and knee-pain results in adults with obesity and osteoarthritis, with analysis and safety context.

Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker
Tracker

Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker

Trial results with population, endpoint, duration and source context. Use the trial finder for recruitment.

Retatrutide FDA Approval Timeline 2026-2028
Tracker

Retatrutide FDA Approval Timeline 2026-2028

Lilly plans a Q1 2027 BLA filing. TRIUMPH-1, -2 and -3 have reported. Approval window late 2027–28.